--- title: Xeltis passes halfway point in pivotal US trial, but regenerative vascular technology still has something to prove description: Xeltis passes halfway point in pivotal US trial, but regenerative vascular technology still has something to prove image: https://medtech-media.com/hubfs/Screenshot%202026-07-15%20161159.png --- [![MedTech media](https://medtech-media.com/hubfs/1-MedTechMedia.svg "MedTech media")](https://medtech-media.com/) [![MedTech media](https://medtech-media.com/hubfs/1-MedTechMedia.svg "MedTech media")](https://medtech-media.com/) - [Cardiology](https://medtech-media.com/cardiology) - [MedTech](https://medtech-media.com/medtech) - [Radiology](https://medtech-media.com/radiology) - [Robotics / Surgical](https://medtech-media.com/robotics-surgical) - [Spine](https://medtech-media.com/spine) - [Urology](https://medtech-media.com/urology) Search - There are no suggestions because the search field is empty. ## [![MedTech media](https://medtech-media.com/hubfs/1-MedTechMedia.svg "MedTech media")](https://medtech-media.com/) [Follow us on LinkedIn](https://www.linkedin.com/in/timlawrieprojectus/) [Follow us on Instagram](https://www.youtube.com/@ScanningtheMarket) [✕](https://medtech-media.com/blog/xeltis-passes-halfway-point-in-pivotal-us-trial-but-regenerative-vascular-technology-still-has-something-to-prove#atbs-offcanvas-primary) - [Cardiology](https://medtech-media.com/cardiology) - [MedTech](https://medtech-media.com/medtech) - [Radiology](https://medtech-media.com/radiology) - [Robotics / Surgical](https://medtech-media.com/robotics-surgical) - [Spine](https://medtech-media.com/spine) - [Urology](https://medtech-media.com/urology) [Newsletter](https://medtech-media.com/blog/tag/newsletter) # Xeltis passes halfway point in pivotal US trial, but regenerative vascular technology still has something to prove By [Phillip Papadimitri](https://medtech-media.com/blog/author/phillip-papadimitri) 15 Jul 2026 [![author](https://medtech-media.com/hubfs/13.png)](https://medtech-media.com/blog/author/phillip-papadimitri) [Phillip Papadimitri](https://medtech-media.com/blog/author/phillip-papadimitri) 15 Jul 2026   Xeltis has exceeded 50% patient enrolment in the US pivotal trial evaluating aXess, its  restorative vascular access device for haemodialysis. More than half of the planned 140 patients have now been recruited across 20 clinical centres in  the United States. The prospective, multicentre study is assessing the safety, performance and  patency of aXess in adults with end-stage renal disease who require vascular access for haemodialysis. Patients will be followed for up to five years. Reaching the halfway point is an important operational milestone for Xeltis. Patient recruitment remains one of the biggest causes of delays in medical device trials, particularly when studies involve complex patients, multiple centres and long-term follow-up. However, the significance of aXess extends beyond trial enrolment. Unlike a conventional synthetic vascular graft designed to remain permanently in the body, aXess uses a bioabsorbable implant intended to provide initial vascular access while encouraging the patient’s own tissue to form a new living vessel. Over time, the implant is designed to be absorbed, leaving behind functional tissue  created through Xeltis’ Endogenous Tissue Restoration technology. This represents an increasingly important direction for cardiovascular innovation. For decades, the medical device industry has largely focused on replacing damaged  anatomy, supporting it mechanically or permanently implanting synthetic materials.  Regenerative technologies propose something more ambitious: providing a temporary  structure that helps the body rebuild itself. It is an attractive proposition, particularly in haemodialysis, where vascular access  remains one of the most persistent challenges facing patients and clinicians. Patients with end-stage renal disease may require dialysis several times each week, placing enormous strain on vascular access sites. Existing options, including arteriovenous fistulas and synthetic grafts, can be affected by complications such as infection, thrombosis, narrowing and repeated interventions. A vascular access conduit capable of transforming into living tissue could potentially  offer a more durable and biologically compatible alternative. But this is also where the industry should remain cautious. “Regenerative” is rapidly becoming one of MedTech’s most attractive labels. It is a  powerful story for investors, clinicians and patients, but biology is rarely as predictable  as engineering. Creating tissue is not automatically the same as creating reliable, durable and clinically  superior tissue. The real test will be whether the vessel formed through aXess can consistently withstand years of repeated needle access while reducing complications and interventions compared with established alternatives. Exceeding 50% enrolment is therefore encouraging, but it should not be confused with  clinical validation. ![Screenshot 2026-07-15 161159](https://medtech-media.com/hs-fs/hubfs/Screenshot%202026-07-15%20161159.png?width=387&height=285&name=Screenshot%202026-07-15%20161159.png) FDA Breakthrough Device Designation, granted to aXess in November 2024, may  support more frequent interaction with the regulator and a more efficient review  process. It does not, however, guarantee approval or commercial success. That distinction matters because MedTech has occasionally become too enthusiastic  about early regulatory milestones. Breakthrough designation is meaningful, but long term clinical outcomes, physician confidence, procedural integration and health economic value will ultimately determine whether a technology changes practice. Xeltis has nevertheless moved beyond being purely a regenerative technology concept. The company has reported clinical progress in Europe and recently began the broader  European commercial rollout of aXess following its first commercial implantation. That  means the technology is now entering the more difficult phase of proving that scientific  innovation can translate into routine clinical adoption. For the wider cardiovascular sector, aXess is worth watching because it reflects a  potential change in how implants are designed. The future may not belong solely to smaller devices, smarter devices or more minimally  invasive devices. It may increasingly belong to implants that are only intended to exist  temporarily, supporting the body before gradually disappearing. That is a compelling vision, but one that must be supported by long-term evidence  rather than regenerative language alone. For now, exceeding 50% enrolment represents a significant step forward for Xeltis and  its US regulatory programme. The next and more important question is whether aXess  can demonstrate that a living vessel is not simply more biologically elegant than a  permanent implant, but meaningfully better for dialysis patients. Congratulations to Eliane Schutte, Paulo Neves, Alexander Goemans, Rob Eyers and  the wider Xeltis team on reaching this milestone.   - [Newsletter](https://medtech-media.com/blog/tag/newsletter) 0 ![Phillip Papadimitri](https://medtech-media.com/hubfs/13.png) [Phillip Papadimitri](https://medtech-media.com/blog/author/phillip-papadimitri) As a MedTech Recruitment Consultant, I help innovative medical technology companies find top talent to drive growth. Connecting companies with the right candidates to navigate an evolving market. Whether you're looking for your next opportunity or hiring for your team, let’s connect. - - [![A Congress Full of Connection, Innovation and Perspective](https://medtech-media.com/hubfs/Screenshot%202026-07-15%20155456.png)](https://medtech-media.com/blog/a-congress-full-of-connection-innovation-and-perspective) [next](https://medtech-media.com/blog/a-congress-full-of-connection-innovation-and-perspective) ### [A Congress Full of Connection, Innovation and Perspective](https://medtech-media.com/blog/a-congress-full-of-connection-innovation-and-perspective) #### Related news ### [Medtronic Backs Anteris with a $90M Strategic Investment](https://medtech-media.com/blog/medtronic-backs-anteris-with-a-us90m-strategic-investment) [![image](https://medtech-media.com/hs-fs/hubfs/13.png?width=35&height=35&length=35&upsize=true&upscale=true&name=13.png)](https://medtech-media.com/blog/author/phillip-papadimitri) [Phillip Papadimitri](https://medtech-media.com/blog/author/phillip-papadimitri) July 15 2026 [Newsletter](https://medtech-media.com/blog/tag/newsletter) ### [Ahead of SRS 2026: Surgical Robotics & AI, What Happens After Approval?](https://medtech-media.com/blog/ahead-of-srs-2026-surgical-robotics-ai-what-happens-after-approval) [![image](https://medtech-media.com/hs-fs/hubfs/14.png?width=35&height=35&length=35&upsize=true&upscale=true&name=14.png)](https://medtech-media.com/blog/author/liam-newton) [Liam Newton](https://medtech-media.com/blog/author/liam-newton) June 26 2026 [Newsletter](https://medtech-media.com/blog/tag/newsletter) ### [HighLife builds momentum in TMVR](https://medtech-media.com/blog/highlife-builds-momentum-in-tmvr) [![image](https://medtech-media.com/hs-fs/hubfs/17.png?width=35&height=35&length=35&upsize=true&upscale=true&name=17.png)](https://medtech-media.com/blog/author/paul-white) [Paul White](https://medtech-media.com/blog/author/paul-white) July 10 2026 [Newsletter](https://medtech-media.com/blog/tag/newsletter) [![MedTech media](https://medtech-media.com/hubfs/1-MedTechMedia.svg "MedTech media")](https://medtech-media.com/) - [Cardiology](https://medtech-media.com/cardiology) - [MedTech](https://medtech-media.com/medtech) - [Radiology](https://medtech-media.com/radiology) - [Robotics / Surgical](https://medtech-media.com/robotics-surgical) - [Spine](https://medtech-media.com/spine) - [Urology](https://medtech-media.com/urology) [Follow us on Facebook](https://www.facebook.com) [Follow us on LinkedIn](https://www.linkedin.com) [Follow us on Twitter](https://www.twitter.com) [Follow us on Instagram](https://www.instagram.com) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Phillip Papadimitri", "url" : "https://medtech-media.com/blog/author/phillip-papadimitri" }, "dateModified" : "2026-07-15T15:16:07.229Z", "datePublished" : "2026-07-15T15:16:07.000Z", "headline" : "Xeltis passes halfway point in pivotal US trial, but regenerative vascular technology still has something to prove", "image" : [ "https://medtech-media.com/hubfs/Screenshot%202026-07-15%20161159.png" ], "mainEntityOfPage" : { "@id" : "https://medtech-media.com/blog/xeltis-passes-halfway-point-in-pivotal-us-trial-but-regenerative-vascular-technology-still-has-something-to-prove", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://medtech-media.com/hubfs/1-MedTechMedia.svg" } } } ```